Diabetic Neuropathy. Insulin-dependent diabetes mellitus, Non-Insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: Case (intervention) group:
after training on drug consumption and emphasis on contact the physician if confronted with drug side effects, they will treated with enalpril (Adibi pharma
Treatment - Drugs
Placebo
Case (intervention) group:
after training on drug consumption and emphasis on contact the physician if confronted with drug side effects, they will treated with enalpril (Adibi pharmaceutical compan
Control group:
treated with placebo (multivitamin from ShahrDarou pharmaceutical company), one tablet daily for three months.
Sponsors
Vice-chancellor for research - Birjand University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Diabetes type 2 diabetes based on the criteria of american diabetes association (blood sugar after 10 to 12 hours of fasting be more than 126 mg/dl or random BS equal or more than 200 mg/dl) at least for 3 years; Having mild to moderate neuropathy (grade 3 to 5 based on Michigan scoring system); Age between 30 to 80 Exclusion criteria: history of enalapril consumption during a recent year; Consumers of alcohol; Kidney disease patients; Liver disease patients (moderate to severe); The existence of a wound in the foot; amputation of the lower extremities; Developing gestational diabetes in women; history of hereditary neuropathy or background diseases causing neuropathy; Taking TCA antidepressants drugs; A lack of vitamin B12 (not less than 160mg / dl); A history of renal arteries stenosis; Having one kidney or micro-albuminuria; Sensitivity to ACD inhibitors; Long-term use of non-steroidal inflammatory drugs such as aspirin during the 4 weeks prior to the disease
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Velocity of nerve conduction. Timepoint: before intervention - after intervention. Method of measurement: EMG-NCV.;Amplitude of nerve conduction. Timepoint: before intervention - after intervention. Method of measurement: EMG-NCV.;Latency (s) of nerve conduction. Timepoint: before intervention - after intervention. Method of measurement: EMG-NCV.;Latency (m) of nerve conduction. Timepoint: before intervention - after intervention. Method of measurement: EMG-NCV. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Rajabpour Sanati
Birjand University of Medical Sciences
Outcome results
None listed